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a  b  s  t  r  a  c  t
Two  different  vaccines,  a 23-valent  polysaccharide  vaccine  (PPV23)  and  a  13-valent  conjugate  vac-
cine  (PCV13),  are  available  for prevention  of  invasive  pneumococcal  disease  (IPD)  in the  population
aged  65  years  and  older  (65+).  The  IPD epidemiology  in the 65+  is undergoing  change  due to  indi-
rect  effects  of  childhood  immunisation.  Vaccine  recommendations  for  the 65+  must  take  into  account
these  trends  in epidemiology.  We  therefore  explored  the  preventive  potential  of vaccination  strate-
gies  to prevent  IPD  in the  65+,  including  PPV23,  PCV13  or PCV13  +  PPV23  in 2014–2019.  Quasi-Poisson
regression  models  were  ﬁtted  to 2004–2014  population-wide  surveillance  data  and  used  to  pre-
dict  incidences  for  vaccine-type  and  non-vaccine  type  IPD.  We  determined  the number  of  people
needed  to be vaccinated  to  prevent  one  case  per season  (NNV)  for each  strategy  and  estimated  the
public  health  impact  on  the  IPD  case  counts  from  increasing  the  vaccine  uptake  to  28–45%. Our
results  indicate  that  PCV13-IPD  will  decrease  by  71%  from  58  (95%  prediction  interval  55–61)  cases
in  2014/15  to 17  (6–52)  in  2018/19  and  PPV23-IPD  by 32%  from  168 (162–175)  to 115  (49–313)
cases.  The  NNV  will  increase  over  time  for  all strategies  because  of  a decreasing  vaccine-type  IPD
incidence.  In  2018/19,  the  PCV13-NNV  will  be 5.3  times  higher  than  the  PPV23-NNV.  Increasing  the
vaccine  uptake  will  lead to a larger  public  health  impact  for all scenarios.  Combining  PCV13  and
PPV23  is most  effective,  but  the  additional  effect  of PCV13  will  decrease  and  is  only marginal  in
2018/19.  Our  study  demonstrates  the  importance  of  increasing  PPV23  uptake  and  of  developing  vaccines
that  confer  broader  immunity.
ublis©  2015  The  Authors.  P
. IntroductionStreptococcus pneumoniae (pneumococci) are part of our normal
asopharyngeal ﬂora, but can cause severe disease such as invasive
neumococcal disease (IPD; e.g. meningitis, febrile bacteraemia).
Abbreviations: IPD, invasive pneumococcal disease; PCV, pneumococcal conju-
ate  vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent
neumococcal conjugate vaccine; PCV13-7, six additional serotypes that are in
CV13 but not in PCV7; PPV2323, valent polysaccharide vaccine; PPV23-11, Twelve
erotypes that are in PPV23 but not in PCV13; VE, vaccine effectiveness; NVT, Non-
accine serotypes; NIPH, Norwegian Institute of Public Health; MSIS, Norwegian
urveillance System for Communicable Diseases; 95% PI, 95% Prediction intervals;
NV, Number needed to vaccinate; PHIs, Public health impact per future season.
∗ Corresponding author at: Division of Infectious Disease Control, Norwegian Insti-
ute  of Public Health, P.O.Box 4404 Nydalen, NO-0403 OSLO, NORWAY.
el.: +47 21 07 67 80; fax: +47 21 07 65 13.
E-mail address: anneke.steens@fhi.no (A. Steens).
ttp://dx.doi.org/10.1016/j.epidem.2015.01.001
755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unhed  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Older adults aged 65 years and older (further called 65+) are among
the most vulnerable population for IPD. In most Western societies,
pneumococcal vaccination is therefore recommended for the 65+.
In Norway, the 23-valent pneumococcal polysaccharide vaccine
(PPV23) has been recommended to the 65+ since 1996, though
uptake is estimated to be only about 15–30% (unpublished data
NIPH). The effectiveness of PPV23 to prevent pneumococcal dis-
ease in older adults remains subject of controversy (Shapiro et al.,
1991;Moberley et al., 2013;Huss et al., 2009;Jackson et al., 2003).
Recently, a 13-valent pneumococcal conjugate vaccine (PCV13)
was licenced in the EU for use in all age groups (European Medicines
Agency, 2013), and at present both PPV23 and PCV13 are available
for prevention of IPD in the 65+. Twelve of the PCV13 serotypes
are also included in PPV23. PCV13 likely provides better protec-
tion against pneumococcal disease due to different immunogenic
properties (Bonten et al., 2014). PCV13 has been used in the
Norwegian childhood immunisation programme since 2011. In
order to make an informed choice between PPV23 and PCV13 for
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dA. Steens et al. / Epi
he 65+ population, evaluation of the preventive potential of the
accines is needed.
The potential of a vaccine to prevent disease depends on the
ncidence of disease caused by serotypes that are covered by the
accine, the vaccine effectiveness (VE) and the vaccine uptake.
ike in other settings where PCV has been implemented in child-
ood immunisation programmes (Lexau et al., 2005;Miller et al.,
011;Harboe et al., 2014), the epidemiology of IPD in Norway has
ubstantially changed, both by direct protection of immunised chil-
ren, and by indirect protection due to decreased transmission
f vaccine serotype pneumococci to non-vaccinated age groups
Steens et al., 2013). Simultaneously, the incidence of IPD caused
y non-vaccine serotypes (NVT) has slightly increased as a result
f serotype replacement (Weinberger et al., 2011;Hicks et al.,
007;Miller et al., 2011;Steens et al., 2013). Further changes in the
PD epidemiology are expected for the near future, as it will take
ome years before the serotype distribution has stabilised after
witching to PCV13 (Hanage et al., 2010). Such future changes in
PD epidemiology should be accounted for when designing vaccine
ecommendations.
The aim of this work was to estimate the number of IPD cases
aused by vaccine serotypes and NVT among the 65+ in the near
uture (2014–2019) using interrupted time series analyses based on
opulation-wide surveillance data from 2004 through mid-2014.
urthermore, we aimed to determine the number of people needed
o be vaccinated (NNV; Kelly et al., 2004) with PCV13 and/or PPV23
o prevent one IPD case per season and to calculate the potential
ublic health impact on IPD of scenarios with different levels of
accine uptake. Although the question of which vaccine to use in
lder adults has been addressed by others (Jiang et al., 2012; Smith
t al., 2012; Vila-Corcoles and Ochoa-Gondar, 2013; Fedson and
uppy, 2013; Jiang et al., 2014), to our knowledge this study is the
rst to compare different vaccine strategies by predicting the public
ealth impact based on data obtained in the PCV13 era.
. Methods
.1. Data sources
In Norway, notiﬁcation of IPD is mandatory for microbiological
aboratories and medical doctors and it is assumed to have a high
nd stable coverage. We  used the serotype-speciﬁc notiﬁcation
ata from the Norwegian Surveillance System for Communicable
iseases (MSIS; Norwegian Institute of Public Health, 2011) for IPD
ases with a testing date between 1 January 2004 and 30 June 2014
nd aged 65+. Data were extracted on 23 July 2014. All IPD cases,
eﬁned as a case in which S. pneumoniae was isolated from a nor-
ally sterile site, are notiﬁable to MSIS. Over 98% are isolated from
lood and/or CSF and more than 90% of isolates are serotyped using
he Quellung reaction with serotype-speciﬁc antisera (Vestrheim
t al., 2010). According to the MSIS regulations, the NIPH does not
equire ethical approval for the use of notiﬁed data for this type of
tudy.
Statistics Norway provided data on the number of Norwegian
nhabitants per age group at the 1st of January of each corre-
ponding year (Statistics Norway, 2014a), as well as predicted
opulation sizes for the future (Statistics Norway, 2014b). We  used
he predicted population size at median growth and used linear
nterpolation to determine monthly population sizes as denomina-
or. In 2014, Norway had 5.1 million inhabitants, of which 821,558
16%) were 65+..2. Interrupted time series analyses
We  categorised our data by vaccine-type using the following
esignation: PCV13 serotypes, serotypes that are covered by PPV23s 11 (2015) 24–31 25
but not by PCV13 (PPV23–12), and NVT, deﬁned as all serotypes not
covered by PCV13 or PPV23; see Table 1.
Data were aggregated by months. Overall 7% (305/4365) of iso-
lates missed serotype information; 58% of missings occurred in
2004/2005. Imputation of missing values was performed according
to the distribution of known serotypes in the respective month, the
preceding and the following month. The notiﬁed monthly IPD cases
Yt were regressed using a Poisson segmented time series analysis
incorporating the changes in the Norwegian childhood immunisa-
tion programme, the population size and correcting for seasonality:
Yt = exp(log(Popt) + ˇ0 + ˇ1 × montht + ˇ2 × monthPCV7t
+ ˇ3 × monthPCV13t + ˇseasonalk + εt) (1)
where montht is the number of months from the start of the study
period in January 2004, and monthPCV7t and month
PCV13
t are the
numbers of months after the introduction of PCV7 vaccination in
July 2006 and the switch to PCV13 vaccination in April 2011, respec-
tively; before the interventions these variables are set to zero. The
term ˇ0 is the intercept coefﬁcient, ˇ1 is the initial trend, ˇ2 is the
change in trend post introduction of PCV7 vaccination, ˇ3 is the
change in trend post introduction of PCV13 vaccination, ˇseasonalk
is the seasonality factor variable at month k = 1, 2..12, and εt is the
error. To account for changes in the population size, the Norwe-
gian population at month t (Popt) was used as an offset. To account
for additional variation, we included a dispersion parameter, ,
resulting in a quasi-Poisson model.
The model Eq. (1) was  ﬁtted separately to PCV13 serotypes,
PPV23–12 serotypes and NVT from 2004 through June 2014 (126
months; Fig. 1). Non-signiﬁcant parameters (p ≥ 0.05) were dis-
carded from the ﬁnal models; see Table 1. Data were analysed using
GLM with the MASS package in the statistical software R version
3.1.0 (Swiss Federal Institute of Technology Zurich, 2014). The ﬁt-
ted models were used to predict IPD case counts for the period July
2014–June 2019 (60 months).
Seasons were deﬁned to run from July to June the following
year (e.g. July 2004–June 2005). Seasonal counts were calculated
by summing the respective monthly counts. The PPV23 counts
were calculated by adding the predicted values of the PCV13 and
PPV23–12 models. Note that our PPV23 counts therefore include
the counts for PCV13 serotype 6A, which is not included in PPV23.
Due to low numbers, it was  not possible to model this serotype
separately and had limited effect on the ﬁnal model. The frequency
of serotype 6A decreased from an average of 24 cases per sea-
son in 2004–2009 to 11 in 2009/10 and further to two 6A cases
in 2013/14.
2.3. The prediction intervals
We determined the 95% prediction intervals (95% PI) by tak-
ing into account both the variation related to the uncertainty in
the parameters (systematic part) and the uncertainty related to the
future trend. First, we performed residual bootstrapping (N = 1000)
and reﬁtted the models to account for the systematic part of the
variation. Then, for each of the 1000 samples, we introduced uncer-
tainty in the predicted trend by adding a random component in
terms of a random walk procedure (Pearson, 1905). In each time
step (month), a random normally distributed number with mean
zero and standard deviation 0.00137 was  drawn and the cumulated
values were exponentiated and added to the predicted values. This
procedure was  repeated 1000 times for each bootstrap sample and
the 95% PI was  obtained as the 2.5% and 97.5% values of the sorted
counts in each season. The value of 0.00137 was chosen based on
preliminary simulations and corresponded to a change of 5% in the
trend of the PCV13 counts.
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Table 1
Overview of the variables and their parameters of each vaccine-type speciﬁc quasi-Poisson regression model. If no parameter estimate is presented, the variable was  discarded
from  the ﬁnal model. The monthly denominator was included in all models as offset.
PCV13 PPV23-12 NVT
Included serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F, 23F
2, 8, 9N, 10A, 11A, 12F,
15B/C, 17F, 20, 22F, 33F
All serotypes not included in
PCV13 or PPV23
Variables Estimate p value Estimate p value Estimate p value
Intercept ˇ0 −9.679 <2exp-16 −11.447 9.06exp-06 −12.153 <2exp-16
Time  trend from January 2004 ˇ1 0.006 <2exp-16
Change in time-trend from PCV7 introduction ˇ2 −0.015 <2exp-16 0.015 1.89exp-08
Change in time-trend from the switch to PCV13 ˇ3 −0.012 0.009 −0.011 0.011 −0.015 1.59exp-02
ˇsesonalk January Reference Reference Reference
February −0.222 0.023 −0.229 0.092 −0.384 0.061
March −0.071 0.445 −0.197 0.142 −0.019 0.917
April  −0.089 0.345 −0.165 0.213 −0.323 0.106
May  −0.174 0.072 −0.269 4.96exp-02 −0.093 0.618
June  −0.483 1.18exp-05 −0.561 2.37exp-04 −0.441 3.33exp-02
July  −0.814 4.87exp-10 −0.689 3.60exp-05 −0.710 2.94exp-03
August −1.222 2.52exp-14 −0.978 0.000 −0.814 1.02exp-03
September −0.260 0.011 −0.605 0.000 −0.408 0.055
October −0.120 0.217 −0.479 0.002 −0.381 0.069
November −0.099 0.309 −0.316 0.027 −0.436 0.041
96 
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Dispersion parameter  1.250 
Residual deviance (degrees of freedom) 141.25 (112) 0.0
.4. Number needed to vaccinate
The NNV is analogous to the number needed to treat (Laupacis
t al., 1988). In the present context, the NNV indicates the number
f people aged 65+ who need to be vaccinated in a certain sea-
on to prevent one IPD case in that same season and age group.
e determined the NNV for three vaccination strategies, PPV23-
nly, PCV13-only or use of PCV13 and PPV23 combined, using the
ethod described by Kelly et al., 2004:
NV = 1/Incunvac × VE (2)
here Incunvac is the seasonal incidence in the unvaccinated pop-
lation, which was calculated by dividing the predicted seasonal
accine-type count, Yˆ s, by the size of the unvaccinated population;
ee Eq. (3). The size of the unvaccinated population was determined
y correcting the predicted population size, Pops, for the assumed
mmunised population:
ncunvac = Yˆ s/(Pops − (Pops × PPV23 uptake × VE PPV23)) (3)
The PPV23 uptake was assumed at 22% (median of the estimated
accine uptake in Norway; unpublished data NIPH). We  used VE
0% (range 40–70) for PPV23 (Table 2), and 75% (range 55–90)
or PCV13 guided by results of the CAPiTA study (Bonten et al.,
014). In the combined scenario (PCV13 + PPV23), we  used the VE of
CV13 for the PCV13 serotypes and the PPV23-VE for the PPV23–12
erotypes. We  used the point estimates for VE to determine the
ost plausible NNV and the lower and upper bounds to deter-
ine its uncertainty. It is known that the VE is lower for some risk
roups compared to the 65+ population without comorbidities (see
or review Steens et al., 2014a). However, since this study focused
n the general 65+ population this was not taken into account.
ig. 1. Graphical representation of the period with observed and with predicted data. The
CV13  (April 2011).0.115 0.360 0.106 0.560
0.971 1.203
117.32 (112) 0.347 138.67 (112) 0.044
2.5. Public health impact of increased uptake of the different
vaccines
We  determined the public health impact per future season
(PHIs) by calculating the additional number of cases prevented by
the three vaccination strategies, PPV23, PCV13 or PCV13 + PPV23,
at different levels of vaccine uptake, which would not have been
prevented if the current scenario with PPV23-only used by 22% of
the 65+ would continue.
PHIs = (Scenario level uptake − initial uptake) × VE × Yˆ s (4)
The PHIs for the combined scenario was determined by com-
bining the PHIs for PCV13 with the PHIs for PPV23–12. The scenario
levels for vaccine uptake were 28%, 36% or 45% in the 65+ popula-
tion. These scenarios were partly based on the estimated inﬂuenza
vaccine uptake in Norway in 2012/2013 (28% without underly-
ing condition, 36% among the general 65+ population; personal
communication KM Rydland, NIPH, 11 April 2014). Similar to the
calculation of NNV, we  used the point estimates of the predicted
seasonal counts and VE to calculate the most plausible PHIs, while
the lower and upper bounds were used to quantify its uncertainty.
We did not take into account waning immunity, but instead we
used a constant value of VE for all ﬁve predicted seasons. The dura-
tion of protection of PPV23 is considered to be longer than 5 years
(Andrews et al., 2012;Ochoa-Gondar et al., 2014), while currently
no data is available for PCV13. We assumed that PCV13 vaccina-
tion would be initiated in the 65+ in 2014/15, and that the level
of uptake of the vaccines would be reached within that season,
with the exception for PCV13 because of the following: in Norway,
PCV13 is recommended to be given at least 3 years after the last
PPV23; PPV23 should be repeated every 10 years (Steens et al.,
2014a). People who  were vaccinated within the last three seasons
 syringes present the time that PCV7 was  introduced (July 2006) and the switch to
A. Steens et al. / Epidemics 11 (2015) 24–31 27
Table  2
Literature overview of estimates of the effectiveness of PPV23 to prevent vaccine-type IPD in the 65+. If different clinical pictures or age groups were used in the study, this
is  indicated in the table between brackets. Note that most of the empirical studies that are presented are also included in the meta-analyses..
Reference Kind of study Study period VE (95%C.I.)
Butler et al., 1993 Indirect cohort analysis on
surveillance data
1978–1992 70 (30–78) [immune-competent 65–74 years]
78  (54–89) [immune-competent ≥75 years]
Shapiro et al., 1991 Case-control study 1984–1990 80 (51–92)/71 (30–88) [65–74 years; <3 years/3–5 years after
vaccination]
67 (20–87)/53 (−15 to 88) [75–84 years; <3/3–5 years]
46 (−31 to 78)/22 (−90–68) [≥85 years; <3/3–5 years]
Honkanen et al. 1999 Non-randomised trial 1993–1994 60 (−40 to 90)
Jackson et al., 2003 Retrospective cohort study 1998–2001 44 (7–67) [bacteraemia]
Andrews et al. 2004 Indirect cohort analysis on
surveillance data
1997–1998,
2001–2002
79 (−14 to 96)
Dominguez et al. 2005 Case-control study with
hospital controls
2001–2002 64 (31–82)
Mooney et al. 2008 Screening method on
surveillance data
2003–2004 62 (45–73) [all-serotype IPD]
Vila-Corcoles et al. 2010 Case-control study 2002–2007 77 (40–92) [population 60+]
Andrews et al., 2012 Indirect cohort analysis on
surveillance data
1998–2010 48 (32–60) [<2 years after vaccination]
24 (10–36) [overall]
Hutchison et al. 1999 Meta-analysis 1966–1996 83 (69–91)
Melegaro and Edmunds, 2004 Meta-analysis 1985–1999 65 (−49 to 92)
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Moore et al. 2000 Meta-analysis 19
ere therefore not yet eligible to receive PCV13. The resulting lev-
ls of vaccine uptake that have been used in Eq. (4) are presented
n Table 3.
Analyses were done in R (http://www.r-project.org/), Stata 13
nd Excel 2010.
. Results
.1. Change in IPD trends following childhood vaccination
During the study period, 4365 IPD cases aged 65+ were noti-
ed in Norway, corresponding to 49% (4365/8847) of all notiﬁed
PD cases. The IPD case counts showed clear seasonality with high
ounts in the winter and signiﬁcantly lower counts in the summer
Fig. 2; Table 1).
The average number of 65+ cases per season decreased from
98 (incidence 73/100,000) in 2004–2006 before the introduction
f PCV7 to 400 (54/100,000) in 2010/11 before switching to PCV13.
his dropped further to 274 (34/100,000) in 2013/14; see Table 4.
he percentages of IPD cases caused by PCV13 and PPV23 serotypes
ecreased from 80% and 89% in 2004/05, respectively, to 26% and
4% in 2013/14.
Overall, the models ﬁtted well the observed monthly IPD case
ounts (Fig. 2). The estimated number of IPD cases caused by
CV13 serotypes decreased signiﬁcantly from the moment PCV7
as introduced, and the switch to PCV13 led to a further decline in
ases (Fig. 2; Table 1). Both PPV23–12 and NVT IPD counts increased
able 3
xample of the calculation of the level of vaccine uptake (=scenario – initial uptake) tha
ere  we only present the scenario level of 36%. Note that PCV13 is recommended to be g
Steens et al., 2014a).
PPV23 PCV13 
2014/15 14% PPV23 a 29.4% PCV
2015/16 14% PPV23 a 31.6% PCV
2016/17 14%PPV23 a 33.8% PCV
2017/18 14% PPV23 a 36% PCV13
2018/19 14% PPV23 a 36% PCV13
a 14% = scenario level 36% – initial uptake of 22%.
b The PCV13 level = scenario level 36% – the population that is not yet eligible for PCV1
opulation that has initially been vaccinated (22%) is ineligible for vaccination, the secon00 32 (−18 to 61)
00 47 (−94 to 86) [bacteraemia]
slightly in the period before the switch to PCV13. After switching
to PCV13, the increase was  halted for NVT-IPD, and the PPV23–12
IPD counts decreased slightly.
3.2. Trends for the near future
Our models predicted a continued decrease in PCV13-IPD counts
in the near future, with an estimate of 17 (95% PI 6–52) cases in
2018/19, representing 8% of the total IPD case counts (Table 4).
At that time, the PPV23–12 IPD count is predicted at 98 (95%
PI 33–295) cases. Taken together, the results suggest a declin-
ing trend in PPV23-IPD counts to 52% of the total case counts in
2018/19; however, the prediction intervals are wide and inconclu-
sive (Table 4). NVT-IPD counts may  show a small increase to 104
cases (95%PI 35–313) in 2018/19, then accounting for 48% of the
cases.
3.3. Number needed to be vaccinated to prevent one IPD case
Despite a higher VE for PCV13 than for PPV23, the NNV was
larger for PCV13 because of its lower vaccine-type IPD incidence
(Table 5). To prevent one IPD case in 2014/15, 16,524 persons
(uncertainty 13,770–22,533) should be vaccinated with PCV13-
only or 7149 (6128–10,724) with PPV23-only. This value will
increase to 60,910 (50,759–83,060) and 11,508 (9864–17,262) in
2018/19, respectively; a 5.3 times difference between PCV13 and
PPV23. The combination of PCV13 and PPV23 will have the lowest
t was used to predict the public health impact of PPV23, PCV13 or PPV23 + PCV13.
iven at least 3 years after the last PPV23; PPV23 should be repeated every 10 years
PCV13 + PPV23
13 b 29.4% PCV13 and 14% PPV23–12
13 b 31.6% PCV13 and 14% PPV23–12
13 b 33.8% PCV13 and 14% PPV23–12
 36% PCV13 and 14% PPV23–12
 36% PCV13 and 14% PPV23–12
3 vaccination because of recent PPV23 vaccination. In the ﬁrst season, 3/10 of the
d season 2/10 × 22% and the third season 1/10 × 22%.
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(ig. 2. The observed data (in green) and predicted monthly number of IPD cases (in
erotype 6A), D: NVT. The arrows indicate the timing of vaccine introduction.
NV, indicating the largest preventive effect. Because of the further
ecrease in vaccine-type IPD incidence, the NNV will increase over
ime for all scenarios.
.4. Public health impact of increased uptake of the different
accines
The combination of PCV13 and PPV23 is found to prevent most
ases during all predicted seasons and at all investigated levels of
accine uptake (Fig. 3), although the difference compared to PPV23-
nly is predicted to be only three cases in 2018/19. Increasing the
accine uptake will lead to a larger public health impact; an increase
able 4
bserved and predicted number of IPD cases aged ≥65 year per season (July–June), by va
ercentage of all IPD cases in its season caused by serotypes covered by the respective vac
95%PI) is presented in brackets.
Surveillance data PCV13 (%) 
Pre-vaccination 2004/05 416 (80) 
2005/06 377 (79) 
PCV7  period 2006/07 395 (82) 
2007/08 292 (66) 
2008/09 271 (64) 
2009/10 179 (50) 
2010/11 205 (51) 
PCV13 period 2011/12 162 (45) 
2012/13 118 (36) 
2013/14 71 (26)
Predicted results PCV13 (95%PI) 
PCV13 period 2014/15 58 (55–61) 
2015/16 43 (35–54) 
2016/17 32 (20–50) 
2017/18 23 (11–50) 
2018/19 17 (6–52) 
a Note that for the predicted results, PPV23 includes serotype 6a, as this estimate was d with 95% prediction intervals (in red). A: PCV13, B: PPV23–12, C: PPV23 (including
in PPV23 uptake affects the public health impact more substantially
than an increase in PCV13 uptake, mainly as a results of the steeper
decrease in PCV13-IPD incidence compared to PPV23–12 IPD inci-
dence. The impact of all scenarios will decrease over time as a result
of the decrease in vaccine-type IPD counts.
The public health impact of a scenario where vaccination with
PCV13 is added to the 22% of 65+ that are currently vaccinated
with PPV23 is estimated to prevent additionally 7 (5–8) cases in
2014/15, which is similar to the expected impact from increas-
ing the PPV23-only uptake to 28%, which may  prevent further 6
(4–7) cases. These numbers will have decreased to 3 (2–3) and 4
cases (3–5) in 2018/19, respectively. At a higher level of vaccine
ccine-type. Behind the observed number of IPD cases in the surveillance data, the
cines is presented in brackets. For the predicted results, the 95% prediction interval
PPV23–12 (%) PPV23 (%) NVT (%)
61 (12) 461 (89) 43 (8)
74 (16) 431 (91) 25 (5)
65 (13) 423 (88) 23 (5)
101 (23) 370 (84) 49 (11)
106 (25) 347 (81) 49 (12)
109 (30) 277 (77) 69 (19)
108 (27) 303 (76) 88 (22)
117 (32) 274 (76) 83 (23)
133 (40) 247 (74) 82 (25)
106 (39) 175 (64) 97 (35)
PPV23–12 (95%PI) PPV23a (95%PI) NVT (95%PI)
110 (105–116) 168 (162–175) 95 (90–101)
107 (86–133) 150 (127–178) 98 (78–122)
104 (66–164) 135 (96–199) 100 (63–159)
100 (48–214) 124 (70–241) 102 (48–218)
98 (33–292) 115 (49–313) 104 (35–313)
etermined based on the sum of the prediction by models PCV13 and PPV23–12.
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Table  5
Number needed to vaccinate to prevent one IPD case per season (July–June), presented by vaccine-type. As VE we used for PPV23: 60% (range 40–70), and for PCV13: 75%
(range  55–90).The uncertainty, presented between brackets, is determined by the uncertainty in VE.
Season PPV23a PCV13 PCV13 + PPV23
2014/15 7149 (6128–10,724) 16,524 (13,770–22,533) 6580 (5577–9492)
2015/16 8223 (7048–12,334) 22,896 (19,080–31,222) 7672 (6514–11,135)
2016/17 9315 (7,985–13,973) 31,725 (26,438–43,261) 8799 (7482–12,842)
2017/18 10,413 (8926–15,620) 43,959 (36,632–59,944) 9942 (8467–14,583)
2018/19 11,508 (9864–17,262) 60,910 (50,759–83,060) 11,089 (9456–16,336)
a Including serotype 6A.
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fig. 3. The public health impact: the predicted number of IPD cases prevented by
omparison to the current scenario (PPV23-only at 22% uptake). A: 28% vaccine up
ealth  impact based on the uncertainty in VE.
ptake, an increase in PPV23-only uptake will have a larger effect
han adding PCV13, and PPV23 will account for a larger proportion
f the impact of the combined regimen (Fig. 3).
. Discussion
We  have shown that the implementation of PCV in the child-
ood immunisation programme has substantially decreased the
CV13-IPD incidence among the 65+ as a result of indirect pro-
ection. The number of IPD cases will likely continue to decrease
urther, with limited or no increase in NVT-IPD. The NNV for PCV13
ill consequently increase considerably. The potential for PCV13
o prevent IPD in the 65+ in Norway will therefore be limited. In
he longer run, increasing PPV23 uptake will have a higher public
ealth impact than adding PCV13 to PPV23 with unchanged lev-
ls of vaccine uptake. An increased vaccine uptake with PCV13 and
PV23 combined will prevent most cases, although the additional
ffect of PCV13 will decrease and is only marginal in 2018/19.
This study focused on IPD, while the highest burden of pneu-
ococcal infections is on lower respiratory tract infections/non-
nvasive pneumonia. Can we extrapolate the results from this study
o non-invasive pneumonia? Although PPV23 is thought to be effec-
ive in preventing IPD in older individuals, particularly in healthy
ndividuals under 75 years (Moberley et al., 2013;Andrews et al.,
012), its protection against non-invasive pneumonia is debated
Moberley et al., 2013; Melegaro and Edmunds, 2004; Jackson et al.,
003; Ochoa-Gondar et al., 2014). PCV13 can prevent about half
f the PCV13-pneumonia cases aged 65+ (Bonten et al., 2014). So,
here might be a potential for PCV13 in pneumonia prevention.
here is no information available about the incidence of PCV13-
neumonia in Norway. Results of a large trial among 65+ in the
etherlands estimated that about 14% of all community acquired
neumonia cases were caused by PCV13 serotypes (Bonten et al.,
014). Note that in the Netherlands, the 10-valent PCV instead of
CV13 is used in children. PCV13-serotypes have been shown to be
ess often the cause of non-invasive compared to invasive pneumo-
occal pneumonia (Benﬁeld et al., 2013). Together with the further
ecrease in PCV13-IPD incidence, this suggests also a limited role
or PCV13 in pneumonia prevention in Norway. Still, more research (dark grey), PCV13 (light grey) and a combination of PCV13 and PPV23 (grey) in
: 36% uptake, C: 45% uptake. The error bars indicate the uncertainty in the public
is needed on the incidence of PCV13-pneumonia to estimate its real
preventive potential in the 65+.
We used a simple statistical prediction model ﬁtted on notiﬁca-
tion data. We explored several ways of implementing the changes
in the childhood immunisation programme in the model, including
constant intervention effects and a gradual build-up of the inter-
vention effect. As the more complex models did not signiﬁcantly
improve the model ﬁt, we  decided on using a simple approach as a
time trend starting at the moment of intervention. We modelled the
vaccine-type serotypes in groups instead of individual serotypes
as this has been shown to provide the best estimates for changes
in IPD incidence (Weinberger et al., 2013). The advantage of our
approach is that we did not need to make assumptions on the
size of the indirect effect and serotype replacement, as these were
intrinsic to the data. Still, the predictions are based on extrapo-
lation of current trends. To prevent too strict conclusions for the
future, we  added stochasticity to our prediction intervals through
a random walk process. Data on pneumococcal carriage in children,
the main transmitters of pneumococci, indicate that the substan-
tial indirect protection of PCV13 is indeed likely to continue in the
future (Lee et al., 2014; Gounder et al., 2014; van Hoek et al., 2014;
Ricketson et al., 2014; Steens et al., 2014b). It is unlikely that use
of PCV13 among the 65+ will induce indirect protection because
of the low carriage rates among older age groups (<5%; Flamaing
et al., 2010). The very limited or absence of serotype replacement
as predicted by our models is less certain, as reﬂected in the wide
95%PIs. Several studies indicate that serotype replacement may  be
occurring after switching to PCV13, though to a lesser degree than
that observed after PCV7 introduction (Moore et al., 2014;Steens
et al., 2013;Kaplan et al., 2013). As it was shown after PCV7
implementation that serotype replacement was  complete only
after a few years (Hanage et al., 2010), serotype replacement might
still occur. If serotype replacement will still occur, depending on the
replacing serotypes, PPV23 may  have larger public health impact
than predicted by this study.
The NNV and public health impact are dependent on the
assumption on the initial level of vaccine uptake. The vaccine
recommendations for risk-groups changed in May  2013, such
that patients with certain comorbidities are recommended to use
PCV13 in addition to PPV23, but for the general 65+ population,
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PV23 is still the only recommended vaccine (Steens et al., 2014a).
lthough the exact vaccine uptake among the 65+ is unknown,
ata on the number of vaccines sold for common risk-groups
including the 65+) indicate that PPV23 uptake has not changed
ubstantially (unpublished data NIPH). If we have underesti-
ated the current vaccine uptake for PPV23, the estimated NNV
ould be higher for PPV23 but lower for both, the PCV13-only
cenario and the scenario with combined use of PCV13 and
PV23. Furthermore, the public health impact of PPV23-only
nd the combined scenario would be lower, while the impact of
CV13 would basically be unchanged. Note that all public health
mpact scenarios are presented in comparison to the baseline
cenario where PPV23 was  used at a level of 22%. Unfortunately
e were not able to compare the public health impact of the
ifferent vaccination scenarios to a scenario in the absence of
ny pneumococcal vaccination, as we estimated the future inci-
ence by ﬁtting notiﬁcation data from a period where PPV23 had
een recommended for the 65+. The public health impact of a
CV13-only strategy would be slightly larger in a scenario where
PV23 vaccination were to cease. However, as the duration of
rotection from PPV23 among those already vaccinated is assumed
o last longer than the number of years we predicted for in this
tudy, the underestimation from using a PPV23 baseline is likely
imited.
Several countries have likewise investigated the best approach
o prevent IPD in older adults. Population-based Markov mod-
lling studies from Germany and UK concluded that vaccination
ith PPV23 remains the optimal vaccination strategy from pub-
ic health and budget perspectives (Jiang et al., 2012;Jiang et al.,
014). A Markov state-transition model used on US data predicted
hat PCV13 will have more impact than PPV23, but only in case of
oderate indirect protection by childhood immunisation (Smith
t al., 2012). A static cohort model on US data showed that a com-
ined strategy would prevent most cases (Chen et al., 2014). A study
sing a more similar approach to ours (Poisson model; Link-Gelles
t al., 2013) concluded on a stable rate of PCV13-IPD, suggesting
hat PCV13 might have a stable preventive potential in the 65+ up
o 2020. None of these models implemented surveillance data of the
CV13 era, and all were sensitive to the size of the indirect effect of
hildhood immunisation. As we used surveillance data up to three
ears after the switch to PCV13, we could implement the real size
f the indirect effect up to mid-2014, and showed that the substan-
ial indirect protection likely decreases the public health impact of
CV13 in Norway.
Pneumococci can be an important cause of super-infections
uring inﬂuenza infections (O’Brien et al., 2000;Kuster et al.,
011;Fleming-Dutra et al., 2013;Talbot et al., 2005). We  therefore
valuated the effect of inﬂuenza illness (including the pandemic
eason) on our estimates by adding the incidence of inﬂuence-like
llness (ILI) determined by the ILI sentinel surveillance (Hauge
t al., 2009) to the models, but this did not signiﬁcantly improve
he models if we already corrected for seasonality. Still, inﬂuenza
accination has been shown to play a role in the prevention of
PD (Christenson et al., 2004;Gilchrist et al., 2012), and in an
ptimal strategy for IPD prevention, pneumococcal vaccination
s combined with inﬂuenza vaccination. Increasing the uptake
f both vaccines is needed. Healthcare providers should be
nvolved in encouraging uptake of vaccination (Schneeberg et al.,
014).
. ConclusionsAlthough our results should be interpreted with caution due to
heir predictive nature, this study suggests that in Norway vaccine-
ype IPD in the 65+ will continue to decrease. Further reductionss 11 (2015) 24–31
in IPD in the era of childhood vaccination can be achieved by
increasing the PPV23 uptake. Still, as the NNV was lowest for the
combination of PCV13 and PPV23, the use of PCV13 and PPV23
combined should be considered for the most fragile population,
including the 65+ with comorbidities, as is currently recommended
in Norway. As the preventive potential of the currently available
pneumococcal vaccines is predicted to decrease, vaccines confer-
ring broader protection should be developed.
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